Firefly BioWorks Announces Strategic Partnership with EMD Millipore
CAMBRIDGE, Massachusetts-- Firefly BioWorks announced today that it has entered into a strategic partnership with EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany. Under the terms of the agreement, EMD Millipore will lead global distribution of the Firefly™ microRNA Assay, the first product to be developed on the Firefly™ Discovery Platform. Marketed by EMD Millipore under the name SmartRNAPlex™, the assay enables rapid profiling of up to 68 microRNA targets per sample in a 96-well plate format using standard flow cytometers.
SmartRNAPlex™ is a powerful new addition to Millipore’s growing portfolio of RNA profiling products. Until now, analyzing large numbers of samples across multiple microRNAs required splitting the samples into parallel qPCR reactions or using low-throughput technologies such as microarrays. SmartRNAPlex™ overcomes this limitation, affording the user both multiplexing and high-throughput capabilities. SmartRNAPlex™ is designed for the large installed base of standard flow cytometers, which significantly decreases adoption costs. This new tool promises to accelerate the pace of microRNA biomarker validation and catalyze the translation of basic biological understanding into clinical diagnostics and drug discovery applications.
To aid with the design of microRNA profiling studies, the company has developed the Firefly™ Discovery Engine. This web-based tool automatically generates a list of the most relevant microRNAs and associated genes for any keyword or topic by parsing the scientific literature.
“By virtue of its flexibility and universality, the Firefly™ Discovery Platform lends itself naturally to profiling a wide array of biomarkers in a multiplexed and rapidly customizable fashion,” said Davide Marini, CEO of Firefly BioWorks. “We are thrilled to work with the leader in benchtop flow cytometry. Our goal is to offer all scientists, especially those facing budget constraints, the opportunity to perform large validation studies that would otherwise require expensive and dedicated instrumentation.”
“We look forward to launching this exciting new product across our line of flow cytometry instruments,” said Anthony Artuso, VP of Strategy and Business Development at EMD Millipore. “As the key role of non-coding RNAs becomes increasingly recognized, we are pleased to announce the inclusion of this microRNA assay in our product line.”
Firefly’s Scientific Advisory Board includes Prof. Victor Ambros, who led the team of scientists that discovered microRNA. The company is funded in part by research grants from the National Cancer Institute under the Small Business Innovation Research (SBIR) program and from the Massachusetts Life Sciences Center. “We are very pleased to see Firefly succeed in the marketplace. This is a great example of how private and public funds can be synergistically utilized to bring new technologies to market, create jobs, accelerate clinical research and ultimately improve patient care,” said Susan Windham-Bannister, Ph.D., President and CEO of the Massachusetts Life Sciences Center.
About Firefly BioWorks
Firefly BioWorks offers an integrated platform for planning, executing and interpreting research studies. Comprising physical assays and bioinformatics tools, this platform is designed to accelerate the identification of relevant biomarkers for clinical diagnostics and drug discovery applications. The technology grew out of pioneering work by Dr. Daniel Pregibon and Prof. Patrick Doyle, both Firefly co-founders, in the Chemical Engineering Department at MIT.
About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of products and services to enable research, development and production of biotechnology and pharmaceutical drug therapies. As one of the top three R&D investors in the Life Sciences Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life sciences research. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees and operations in 67 countries.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.